Compare
AbbVie Inc. vs Eli Lilly & Co vs Bristol Myers Squibb Co vs Abbott Laboratories
| Latest fiscal year | AbbVie Inc. ABBV | Eli Lilly & Co LLY | Bristol Myers Squibb Co BMY | Abbott Laboratories ABT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $61.16B | $65.18B | $48.19B | $44.33B |
| Revenue growth (YoY) | +8.6% | +44.7% | -0.2% | +5.7% |
| Gross margin | 70.2% (computed) | 83.0% (computed) | n/a | 56.4% (computed) |
| Operating margin | 24.6% | n/a | n/a | 18.2% |
| Net margin | 6.9% | 31.7% | 14.6% | 14.7% |
| Net income | $4.23B | $20.64B | $7.05B | $6.52B |
| EPS (Diluted) | $2.36 | $22.95 | $3.46 | $3.72 |
| Operating cash flow | $19.03B | $16.81B | $14.16B | $9.57B |
| Free cash flow | $17.82B | n/a | $12.85B | $7.39B |
| Cash & equivalents | $5.23B | $7.27B | $10.21B | $8.52B |
| Total assets | $133.96B | $112.48B | $90.04B | $86.71B |
| Total liabilities | n/a | n/a | $71.53B | n/a |
| Shareholders' equity | -$3.27B | $26.54B | $18.47B | $52.13B |
| Return on year-end equity | n/a | 77.8% | 38.2% | 12.5% |
| Shares outstanding | n/a | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | AbbVie Inc. | Eli Lilly & Co | Bristol Myers Squibb Co | Abbott Laboratories |
|---|---|---|---|---|
| Latest | $61.16B Ended 2025-12-31 | $65.18B Ended 2025-12-31 | $48.19B Ended 2025-12-31 | $44.33B Ended 2025-12-31 |
| 1 year earlier | $56.33B Ended 2024-12-31 | $45.04B Ended 2024-12-31 | $48.30B Ended 2024-12-31 | $41.95B Ended 2024-12-31 |
| 2 years earlier | $54.32B Ended 2023-12-31 | $34.12B Ended 2023-12-31 | $45.01B Ended 2023-12-31 | $40.11B Ended 2023-12-31 |
| 3 years earlier | $58.05B Ended 2022-12-31 | $28.54B Ended 2022-12-31 | $46.16B Ended 2022-12-31 | $43.65B Ended 2022-12-31 |
| 4 years earlier | $56.20B Ended 2021-12-31 | $28.32B Ended 2021-12-31 | $46.38B Ended 2021-12-31 | $43.08B Ended 2021-12-31 |